Italian Journal of Public Health World

IJPH - Year 8, Volume 7, Number 3, Suppl. 1, 2010
ITALIAN
JOURNAL
OF
PUBLIC
HEALTH
24) Seward JF, Watson BM, Peterson CL et al. Varicella disease
after introduction of varicella vaccine in the United States,
1) Weller TH, Witton HM. The etiologic agents of varicella and
1995-2000. JAMA 2002;287(5):606-11.
herpes zoster; serologic studies with the viruses as propagated
25) Rentier B, Gershon AA, European Working Group on
in vitro. J Exp Med 1958;108(6):869-90.
Varicella. Consensus: varicella vaccination of healthy children2) Hambleton S. Chickenpox. Curr Opin Infect Dis
-a challenge for Europe. Pediatr Infect Dis J 2004;23(5):379-89.
2005;18(3):235-40.
26) Quian J, Rüttimann R, Romero C, et al. Impact of universal
3) Heininger U, Seward JF. Varicella. Lancet 2006;368(9544):1365varicella vaccination of one year-olds in Uruguay: 1997-2005”
76. Erratum in: Lancet. 2007;369(9561):558.
Arch Dis Child 2008; 93 (10): 845-50.
4) Miller E, Vardien J, Farrington P. Shift in age in chickenpox.
27) Reynolds MA, Chaves SS, Harpaz R, As L, Seward JF. The
Lancet 1993;341(8840):308-9.
impact of the varicella vaccination program on herpes zoster
5) Gershon A. Varicella: to vaccinate or not vaccinate? Arch Dis
epidemiology in the United States: a review. J Infect Dis
Child 2000 Jan;82(1):88.
2008;197(Suppl 2):S224-7.
6) Salmaso S, Mandolini D, et al. La prevenzione della varicella
28) Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality
in Italia: strategie di vaccinazione. Ann Ig 2002;14 (Suppl. 6):
due to varicella after implementation of varicella vaccination in
35-44.
the United States. N Engl J Med 2005;352:450-8.
7) Baldo V, Baldovin T, Russo F, et al. Varicella: epidemiological
29) Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A.
aspects and vaccination coverage in the Veneto Region. BMC
Increasing coverage and efficiency of measles, mumps, and
Infect Dis 2009;9:150.
rubella vaccine and introducing universal varicella vaccination
8) Gabutti G, Rota MC, Guido M, et al. The epidemiology of
in Europe: a role for the combined vaccine. Pediatr Infect Dis
Varicella Zoster Virus infection in Italy. BMC Public Health
J 2007;26(7):632-8.
2008;8:372.
30) Hammerschimdt T, Bisanz H, Wutzler P. Universal mass
9) Nardone A, de Ory F, Carton M et al. The comparative serovaccination against varicella in Germany using an MMRV
epidemiology of varicella zoster virus in 11 countries in the
combination vaccine with a two-dose schedule: an economic
European region. Vaccine 20077;25(45):7866-72.
analysis. Vaccine 2007;25:7307-12.
10) Prevention of varicella: Recommendations of the Advisory
31) Thiry N, Beutels P, Tancredi F et al. An economic
Committee on Immunization Practices (ACIP). MMWR 1996;45
analysis of varicella vaccination in Italian adolescents. Vaccine
(11):1-24.
2004;22:3546-62.
11) Azzari C, Massai C, Poggiolesi C, et al. Cost of varicella32) Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux
related hospitalisations in an Italian paediatric hospital:
B. Varicella Vaccination in Italy. An Economic Evaluation of
comparison with possible vaccination expenses. Curr Med Res
Different Scenarios. Pharmacoeconomics 2004;22(13):839-55.
Opin 2007;23(12):2945-54.
33) Bonanni P, Boccalini S, Bechini A, Banz K. Economic
12) Bonsignori F, Chiappini E, Frenos S, Peraldo M, Galli
evaluation of varicella vaccination in Italian children and
L, de Martino M. Hospitalization rates for complicated and
adolescents according to different intervention strategies:
uncomplicated chickenpox in a poorly vaccined pediatric
the burden of uncomplicated hospitalised cases. Vaccine
population. Infection 2007;35(6):444-50. Epub 2007 Nov 22.
2008;26(44):5619-26.
13) Ziebold C, von Kries R, Lang R, Weigl J, Schmitt HJ.
34) Zotti CM, Maggiorotto G, Migliardi A. Costs of varicella.
Severe complication of varicella in previously children in
Ann Ig 2002;14(4 Suppl 6):29-33.
Germany: 1 year survey. Pediatrics 2001; 108(5):e79.
35) Fornaro P, Gandini F, Marin M, et al. Epidemiology and
14) Giaquinto C, Sturkenboom M, Mannino S, Arpinelli F,
cost analysis of varicella in Italy: results of a sentinel study
Nicolosi A, Cantarutti L, per il gruppo di studio sulla varicella in
in the pediatric practice. Italian Sentinel Group on Pediatric
età pediatrica (Pedianet Varicella Study Group) Epidemiologia
Infectious Diseases. Pediatr Infect Dis J 1999;18(5):414-9.
ed esiti della varicella in Italia: risultati di uno studio prospettico
36) Gialloreti LE, Divizia M, Pica F, Volpi A. Analysis of the
sui bambini (0-14 anni) seguiti dai pediatri di libera scelta
cost-effectiveness of varicella vaccine programmes based on
(studio Pedianet). Ann Ig 2002;14 (Suppl. 6): 21-7.
an observational survey in the Latium region of Italy. Herpes
15) Bartolozzi G. Clinical features of VZV infection and its
2005;12(2):33-7.
complications. Ann Ig 2002;14(4 Suppl 6):1-5.
37) Siedler A, Arndt U. Impact of the routine varicella
16) Gabutti G, Azzari Ch. Priorix Tetra: un nuovo vaccino
vaccination programme on varicella epidemiology in Germany.
combinato contro morbillo, parotite, rosolia e varicella.
Euro Surveill 2010;15(13).pii 19530.
Minerva Pediatrica 2008;60:429-41.
38) Spackova M, Wiese-Posselt M, Dehnert M, et al. Comparative
17) Spackova M, Muehlen M, Siedler A. Complications of
varicella vaccine effectiveness during outbreaks in day-care
varicella
after implementation
of routine
Table 1. Focus
groups and methods
of datachildhood
collection varicella
employed in the three studies
centres. Vaccine 2010;28(3):686-91.
vaccination in Germany. Pediatr Infect Dis J 2010:29(9):884-6.
39) Lopez AS, Guris D, Zimmerman L, et al. One dose of
18) Marin M, Güris D, Chaves SS, et al. Prevention of varicella:
varicella vaccine does not prevent school outbreaks: is it time
recommendations of the Advisory Committee on Immunization
for a second dose? Pediatrics 2006;117(6):e1070-7.
Practices (ACIP). MMWR Recomm Rep 2007;56(RR-4):1-40.
40) Marchetti F, Cuccia M. Letter to the editor. Vaccine
19) Ministero della Salute. Database Ricoveri Ospedalieri
2010;28(31):4859-60.
(SDO). Disponibile da: www.salute.gov.it/ricoveriOspedalieri/
41) Giammanco G, Ciriminna S, Barberi I, et al. Universal
ricoveriOspedalieri.jsp.
varicella vaccination in the Sicilian paediatric population: rapid
20) Volpi A, Gentile G, Pica F, Suligoi B, Slavip study group.
uptake of the vaccination programme and morbidity trends
Antiviral treatment of varicella in pediatric practice in the
over five years. Euro Surveill 2009;14(35).pii: 19321.
Latium region of Italy: results of an observational study. Pediatr
42) Cuccia M, Pollina Addario S, Cernigliaro A, Palmigiano V.
Infect Dis J 2002;21(8):739-43.
Ospedalizzazione per varicella in Sicilia dopo l’introduzione
21) Ministero della Salute. Piano Nazionale Vaccini 2005della vaccinazione. BEN Notiziario ISS 2009;22(3).
2007. Disponibile da: http://www.salute.gov.it/imgs/C_17_
43) Prymula R, Bergsaker M, daCosta C, et al. Efficacy of twopubblicazioni_543_allegato.pdf.
dose MMRV and one-dose varicella vaccination in children
22) Ministero della Salute. Vaccinazioni dell’età pediatrica.
aged 12-22 months in 10 European Countries. Espid 2010.
Anno 2008. Disponibile da: http://www.salute.gov.it/
Abstract 622. Disponibile da: http://www.docguide.com/
imgs/C_17_pagineAree_811_listaFile_itemName_10_file.pdf.
news/content.nsf/news/852576140048867C8525771E006B5
23) Bonanni P, Breuer J, Gershon A, et al. Varicella vaccination
A9E.
in Europe - taking the practical approach. BMC Med 2009;7:26.
Bibliografia
S33
IJPH - Year 8, Volume 7, Number 3, Suppl. 1, 2010
ITALIAN
JOURNAL
44) Weinmann S, Chun C, Mullooly JP, et al. Laboratory
diagnosis and characteristics of breakthrough varicella in
children. J Infect Dis 2008;197 (Suppl 2):S132-8.
45) Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO.
Contagiousness of varicella in vaccinated cases: a household
contact study. JAMA 2004;292(6):704-8.
46) Regione Veneto. Sorveglianze speciali malattie infettive.
Anno 2009. Disponibile da http://www.regione.veneto.it/NR/
rdonlyres/6B81C029-0303-4E7F-B24F-B2BF3F3F5251/0/Rappo
rtoMalattieInfettive_1202def.pdf.
47) Edmunds WJ, Brisson M, Gay NJ, Miller E. Varicella
vaccination: a double-edged sword? Commun Dis Public Health
2002;5(3):185-6.
48) Varilrix®. Riassunto delle caratteristiche di prodotto.
49) Varivax®. Riassunto delle caratteristiche di prodotto.
50) Priorix Tetra®. Riassunto delle caratteristiche di prodotto.
51) Proquad®. Riassunto delle caratteristiche di prodotto.
52) Knuf M, Faber J, Barth I, Habermehl P. A combination
vaccine against measles, mumps, rubella and varicella. Drugs
Today (Barc) 2008;44(4):279-92.
53) Czajka H, Schuster V, Zepp F, Esposito S, Douha M,
Willems P. A combined measles, mumps, rubella and varicella
vaccine (Priorix-Tetra): immunogenicity and safety profile.
Vaccine 2009;27(47):6504-11.
54) Vesikari T, Karvonen A, Bianco V et al. Immunogenicity and
safety of the co-administration of the MENACWY-TT conjugate
vaccine with MMRV in toddlers. ESPID 2010. Disponibile da:
www.kenes.com/espid2010/abstracts/pdf/742.pdf.
55) Vesikari T, Baer M, Willems P. Immunogenicity and safety
of a second dose of measles-mumps-rubella-varicella vaccine
in healthy children aged 5 to 6 years. Pediatr Infect Dis J
2007;26(2):153-8.
56) Halperin SA, Ferrera G, Scheifele D, et al. Safety and
immunogenicity of a measles-mumps-rubella-varicella vaccine
given as a second dose in children up to six years of age.
Vaccine 2009;27(20):2701-6.
57) Kreth HW, Lee BW, Kosuwon P, et al. Sixteen years of
global experience with the first refrigerator-stable varicella
vaccine (Varilrix). BioDrugs 2008;22(6):387-402.
58) Capovilla G, Mastrangelo M, Romeo A, Vigevano F.
Recommendations for the management of “febrile seizures”:
Ad Hoc Task Force of LICE Guidelines Commission. Epilepsia
2009;50 (Suppl 1):2-6.
59) Brown NJ, Berkovic SF, Scheffer IE. Vaccination, seizures
and ‘vaccine damage’. Curr Opin Neurol. 2007;20(2):181-7.
60) Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination
and febrile seizures: evaluation of susceptible subgroups and
long-term prognosis. JAMA 2004;292(3):351-7.
61) NINDS. Febrile seizures information page. Disponibile da:
http://www.ninds.nih.gov/disorders/febrile_seizures/febrile_
seizures.htm.
62) Marin M, Broder KR, Temte JL, Snider DE, Seward JF,
Centers for Disease Control and Prevention (CDC). Use of
combination measles, mumps, rubella, and varicella vaccine:
recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 2010;59(RR-3):1-12.
S34
OF
PUBLIC
HEALTH
63) Gillet Y, Steri GC, Behre U, et al. Immunogenicity and
safety of measles-mumps-rubella-varicella (MMRV) vaccine
followed by one dose of varicella vaccine in children aged
15 months-2 years or 2-6 years primed with measles-mumpsrubella (MMR) vaccine. Vaccine 2009;27(3):446-53.
64) Schuster V, Otto W, Maurer L, et al. Immunogenicity and
safety assessments after one and two doses of a refrigeratorstable tetravalent measles-mumps-rubella-varicella vaccine in
healthy children during the second year of life. Pediatr Infect
Dis J 2008;27(8):724-30.
65) Kuter BJ, Brown ML, Hartzel J, et al. Safety and
immunogenicity of a combination measles, mumps, rubella and
varicella vaccine (ProQuad). Hum Vaccin 2006;2(5):205-14.
66) Lieberman JM, Williams WR, Miller JM, et al. The safety and
immunogenicity of a quadrivalent measles, mumps, rubella and
varicella vaccine in healthy children: a study of manufacturing
consistency and persistence of antibody. Pediatr Infect Dis J
2006;25(7):615-22.
67) Knuf M, Habermehl P, Zepp F, et al. Immunogenicity
and safety of two doses of tetravalent measles-mumps-rubellavaricella vaccine in healthy children. Pediatr Infect Dis J
2006;25(1):12-8.
68) Canale Verde. XIII Relazione sull’attività. Dati relativi
al 2009.Disponibile da: http://prevenzione.ulss20.verona.it/
canaleverde.html.
69) Epidemiologisches Bulletin. Aktuelle daten und
informationen zu infektionskrankheiten und public health.
Robert Kock Institute. 17 August 2009/Nr 33.
70) Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccineinduced immunity to varicella over time. N Engl J Med
2007;356(11):1121-9.
71) Kuter B, Matthews H, Shinefield H, Black S et al. Ten
year follow-up of healthy children who received one or
two injections of varicella vaccine. Pediatr Infect Dis J
2004;23(2):132-7.
72) Regione Veneto. Calendario Vaccinale. Disponibile da:
http://www.regione.veneto.it/NR/rdonlyres/E214F858-D0164143-8139-08B16D663145/0/Calendariovaccinalemarzo2008.
pdf.
73) Regione Toscana. Direttive regionali in materia di
vaccinazioni. Disponibile da: http://www.regione.toscana.it/
regione/multimedia/RT/documents/2009/10/02/66c4e7f11e
5ab6d9e05151a72c3784de_direttiveregionalisuvaccinazioni1.
pdf.
74) Regione Basilicata. Calendario vaccinale Regione
Basilicata-2010. DGR 599 dell’8.4.2010.
75) Brisson M, Melkonyan G, Drolet M, et al. Modeling the impact
of one- and two-dose varicella vaccination on the epidemiology
of varicella and zoster. Vaccine 2010;28(19):3385-97.
76) Regione Veneto. Sorveglianze speciali malattie infettive.
Anno 2009. Disponibile da: www.regione.veneto.it/NR/.../0/
RapportoMalattieInfettive_1202def.pdf.
77) WHO/IVB/05.18. Vaccine introduction guidelines. Adding
a vaccine to the national immunizaiton programme. Decision
and implementation. Disponibile da: http://www.who.int/
immunization/documents/WHO_IVB_05.18/en/index.html.